ClinicalTrials.gg
TerminatedNCT03866239Updated Aug 9, 2024

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

A Phase 1 interventional study of Obinutuzumab and Atezolizumab in Colorectal Cancer, sponsored by Hoffmann-La Roche. Terminated at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Why this study was terminated
The Sponsor terminated the study because development of cibisatamab has been discontinued.

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies in Colorectal Neoplasms by Hoffmann-La Roche — 3 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · Hoffmann-La Roche.

Enrollment
56th of 77
47 · median 96
Started
2019
with 1 other
Phase 1
22 of 111
3 open now
Registered
98th of 111
by date

Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 56th largest by enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2019, is one of 22 in phase 1, and was the 98th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

CO40939 is a Phase Ib, open-label, multicenter, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of cibisatamab in combination with atezolizumab administered after pretreatment with obinutuzumab in patients with Stage IV microsatellite stable (MSS) metastatic colorectal cancer (mCRC) whose tumors have high carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression and who have progressed on two or more chemotherapy regimens. The study is composed of a safety run-in and an exploratory part.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma originating from the colon or rectum
  • disease not amenable to local treatment
  • Tumors that are microsatellite stable or microsatellite instability low, as determined by a local, certified laboratory
  • Tumors that have high carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression as determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in an or a fresh tumor biopsy and documented through central testing of a representative tumor tissue specimen performed at baseline
  • Experienced disease progression during or within 3 months following the last administration of approved standard therapies
  • Performance Status of 0 or 1
  • of >= 12 weeks
  • Adequate hematologic and end-organ function
  • Negative test at screening
  • Negative surface antigen test and total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening
  • Negative virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening
  • Negative human T-cell lymphotropic virus type 1 test for participants from endemic countries (Japan, countries in the Caribbean basin, South America, Central America, sub-Saharan Africa, and Malaysia)
  • For women of : agreement to remain abstinent or use methods, agreement to regular pregnancy testing, and agreement to refrain from donating eggs, women must remain abstinent or use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for 5 months after the final dose of atezolizumab, for 4 months after the final dose of cibisatamab, for 18 months after the final dose of obinutuzumab, and for 3 months after the final dose of tocilizumab
  • For men: agreement to remain abstinent or use a condom, and agreement to refrain from donating sperm, with a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 3 months after the final dose of cibisatamab, for 3 months after the final dose of obinutuzumab, and for 2 months after the final dose of tocilizumab to avoid exposing the embryo
  • Lactic acid dehydrogenase (LDH) \</= 2.5 x (ULN)

Additional Inclusion Criteria for patient enrollment into Part 2 of the study:

  • No prior treatment with regorafenib or Trifluridine/Tipiracil (TAS-102)

Exclusion criteria

Exclusion criteria

  • Symptomatic, untreated, or actively progressing central nervous system
  • Non-irradiated tumor lesions > 2 cm at critical sites where tumor swelling induced by cibisatamab is expected to lead to significant complications
  • Dyspnea or peripheral capillary oxygen saturation \< 92% at rest at baseline for patients with bilateral lung lesions or metastases in the remaining lung following lobectomy or pneumonectomy
  • Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for >= 2 weeks prior to initiation of study treatment
  • History of and progressive multifocal leukoencephalopathy
  • Uncontrolled tumor-related pain and pleural effusion or ascites requiring recurrent drainage procedures
  • Participants with pericardial effusion
  • Uncontrolled or symptomatic hypercalcemia
  • Active or history of disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan
  • Active tuberculosis that has required treatment within 3 years prior initiation of study treatment or latent tuberculosis that has not been appropriately treated
  • Uncontrolled hypertension, unstable angina, congestive heart failure of any Class II or greater, serious cardiac arrhythmia requiring treatment and history of myocardial infarction within 6 months prior to initiation of study treatment
  • Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
  • History of other than CRC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer
  • Known active infection, or reactivation of a latent infection, whether bacterial, viral, fungal, mycobacterial, or other pathogens, or any major episode of infection requiring hospitalization or treatment with IV antibiotics
  • Prior allogeneic stem cell or solid organ transplantation
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment or within 5 months after the final dose of atezolizumab
  • Current treatment with anti-viral therapy for
  • Treatment with any systemic anti-cancer therapy, including chemotherapy or hormonal therapy, within 28 days prior to initiation of study treatment
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Prior treatment with any of the protocol-specified study treatments
  • Prior treatment with T-cell bispecifics (TCBs), including CEACAM5-TCB, CD137 agonists or immune checkpoint blockade therapies, including , anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug prior to initiation of study treatment
  • Treatment with systemic medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment
  • Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better with the exception of alopecia of any grade and Grade \<= 2 peripheral neuropathy
  • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  • Known to Chinese hamster ovary cell products
  • Known allergy or hypersensitivity to any of the study drugs or any of their
  • Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab, within 4 months after the final dose of cibisatamab, within 18 months after the final dose of obinutuzumab, and within 3 months after the final dose of tocilizumab
  • Participants with pleural effusion requiring drainage procedures
  • Participants with pleural effusion and/or pleural lesions involving both lungs (i.e. bilateral pleural effusions; unliateral pleural effusion with pleural lesion in the contralateral lung)
  • Participants with >10 bilateral pulmonary lesions (i.e. at least one lesion in each lung and more than 10 lung lesions in total)
  • Participants with pulmonary miliary metastatic pattern (innumerable small lesions) or pulmonary lymphangitic carcinomatosis
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Obinutuzumab Pretreatment (OpT) + Cibisatamab + Atezolizumab

    Participants will receive obinutuzumab approximately 2 weeks before receiving atezolizumab and cibisatamab on Day 1 of each treatment cycle (cycle = 21 days).

    Drug: Obinutuzumab · Drug: Atezolizumab · Drug: Cibisatamab · Drug: Tocilizumab

Interventions

  • Obinutuzumab will be administered by intravenous (IV) infusion as either a split or single dose approximately 2 weeks before Cycle 1, Day 1 (cycle = 21 days).

    Also known as: Gazyva/Gazyvaro

  • Atezolizumab will be administered at a fixed dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.

    Also known as: Tecentriq

  • Cibisatamab will be administered at a fixed dose of 100 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.

  • Tocilizumab will be administered by IV infusion as necessary to manage adverse events (AEs)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events (AEs)

    Time frame: Up to 5 years

  2. Confirmed Objective Response Rate (ORR)

    Time frame: Baseline up to 5 years

Secondary outcomes

  1. Confirmed ORR, as Determined by an Independent Review Facility (IRF) According to Response Evaluation in Solid Tumors version 1.1 (RECIST v1.1)

    Time frame: Up to 5 years

  2. Duration of Response (DOR)

    Time frame: From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 5 years)

  3. Disease Control Rate (DCR)

    Time frame: Up to 5 years

  4. Progression Free Survival (PFS)

    Time frame: From enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 5 years)

  5. Overall Survival (OS)

    Time frame: From enrollment to death from any cause (up to 5 years)

  6. Total Clearance (CL) for Cibisatamab

    Time frame: At pre-defined intervals from Day 1 to progressive disease and/or treatment discontinuation (up to 5 years)

  7. Volume of Distribution at Steady State (Vss) of Cibisatamab

    Time frame: At pre-defined intervals from Day 1 to progressive disease and/or treatment discontinuation (up to 5 years)

  8. Area Under the Concentration-Time Curve (AUC0-t) for Cibisatamab

    Time frame: At pre-defined intervals from Day 1 to progressive disease and/or treatment discontinuation (up to 5 years)

  9. Maximum Serum Concentration (Cmax) of Cibisatamab

    Time frame: At pre-defined intervals from Day 1 to progressive disease and/or treatment discontinuation (up to 5 years)

  10. CL of Atezolizumab

    Time frame: At pre-defined intervals from Day 1, Cycle 1 through Cycle 8 (cycle = 21 days)

  11. Vss of Atezolizumab

    Time frame: At pre-defined intervals from Day 1, Cycle 1 through Cycle 8 (cycle = 21 days)

  12. AUC0-t of Atezolizumab

    Time frame: At pre-defined intervals from Day 1, Cycle 1 through Cycle 8 (cycle = 21 days)

  13. Cmax of Atezolizumab

    Time frame: At pre-defined intervals from Day 1, Cycle 1 through Cycle 8 (cycle = 21 days)

  14. CL of Obinutuzumab

    Time frame: At pre-defined intervals from the start of obinutuzumab pretreatment through Cycle 8 (cycle = 21 days)

  15. Vss of Obinutuzumab

    Time frame: At pre-defined intervals from the start of obinutuzumab pretreatment through Cycle 8 (cycle = 21 days)

  16. AUC0-t of Obinutuzumab

    Time frame: At pre-defined intervals from the start of obinutuzumab pretreatment through Cycle 8 (cycle = 21 days)

  17. Cmax of Obinutuzumab

    Time frame: At pre-defined intervals from the start of obinutuzumab pretreatment through Cycle 8 (cycle = 21 days)

  18. Incidence of Anti-Drug Antibodies (ADAs) to Cibisatamab

    Time frame: Baseline up to 5 years

  19. Incidence of ADAs to Atezolizumab

    Time frame: Baseline up to 5 years

  20. Incidence of ADAs to Obinutuzumab

    Time frame: Baseline up to 5 years

07

Study locations

13 sites
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • UCLA Cancer Center
    Santa Monica, California 90404, United States
  • Stanford Comprehensive Cancer Center
    Stanford, California 94305, United States
  • Yale University
    New Haven, Connecticut 06510, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Duke Cancer Center
    Durham, North Carolina 27710, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Rigshospitalet; Fase 1 Enhed - Onkologi
    København Ø, 2100, Denmark
  • Centre Leon Berard; Departement Oncologie Medicale
    Lyon, 69373, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Hospital Univ Vall d'Hebron; Servicio de Oncologia
    Sant Andreu de La Barca, Barcelona 08740, Spain
  • Clinica Universitaria de Navarra; Servicio de Oncologia
    Pamplona, Navarra 31008, Spain
  • START Madrid-FJD, Hospital Fundacion Jimenez Diaz
    Madrid, 28040, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Mar 2024, 58 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2019
First posted
Mar 7, 2019
StartActual
May 7, 2019
Primary completionActual
Mar 13, 2024
CompletionActual
Mar 13, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03866239
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 7, 2019
Start date
May 7, 2019
Primary completion
Mar 13, 2024
Completion
Mar 13, 2024
Last update
Aug 9, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Obinutuzumab · Cibisatamab

Start the discussion